TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10063567
Drug: 5-year treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-year treatment with tamoxifen
Study: 10063567
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy added to local treatment of isolated locoregional recurrence
Study: 7970004
Drug: Lamotrigine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (200 to 500 mg daily, with higher dosages up to 700 mg in extension studies)
Study: 4947832
Drug: Aluminium-phosphate-adsorbed tetanus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminium-phosphate-adsorbed tetanus toxoid (1-3 injections of 1 ml)
Study: 29145711
Drug: Prehospital antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital antibiotic administration by paramedics
Study: 29145711
Drug: Delayed antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antibiotic therapy
Study: 27149935
Drug: L-DOPA, specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOPA, specific dosage and duration not mentioned
Study: 22185955
Drug: Chiropractic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic treatment (spinal manipulation) for 4 weeks
Study: 10827386
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy after fibrinolytic therapy
Study: 9395034
Drug: Study S8600
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study S8600 (age < 50 years, standard dose cytarabine)
Study: 9395034
Drug: Study S8600
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study S8600 (age < 50 years, high dose cytarabine)
Study: 8383390
Drug: Immune serum
Normalized name: IMMUNE SERUMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune serum globulin (Ig) 0.06 ml/kg
Study: 8383390
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A virus vaccine (iHAV) single dose 25 ng
Study: 8383390
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A virus vaccine (iHAV) booster dose
Study: 3769702
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg after each meal and at bedtime (200 mg qid)
Study: 3769702
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg after breakfast and at bedtime (400 mg bid)
Study: 3052675
Drug: Infiltration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration of lignocaine solution
Study: 24725373
Drug: Bronchodilator use
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator use (salbutamol)
Study: 1817055
Drug: Initial periodontal
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial periodontal therapy consisting of a single subgingival root debridement procedure followed by repeated monthly subgingival irrigations over a period of 6 months
Study: 22315807
Drug: Electro acupuncture
Normalized name: ELECTRODE SPRAY,ELECTRO MIST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro acupuncture therapy (10 sittings on alternate days at GB and UB points)
Study: 22315807
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug therapy (oral Valdecoxib) with supervised physiotherapy
Study: 18445172
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of insulin aspart
Study: 18445172
Drug: Insulin injection
Normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin injection of insulin glargine
Study: 16941338
Drug: Highly active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly active antiretroviral therapy (HAART) for 24 weeks
Study: 14622632
Drug: Individualised fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised fluid prescription (30 ml/kg body weight/24 h, max 35 ml/kg body weight/24 h)
Study: 14622632
Drug: Standard fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluid intake (maximum 1.5 l)
Study: 29602346
Drug: Grafted facemask
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grafted facemask therapy
Study: 29602346
Drug: Ungrafted facemask
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ungrafted facemask therapy
Study: 29602346
Drug: Facemask therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facemask therapy (grafted and ungrafted)
Study: 27195774
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) with erythropoietin (EPO) - 1 g IV FCM plus 40,000 IU subcutaneous EPO
Study: 27195774
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) without erythropoietin (EPO) - 1 g IV FCM plus subcutaneous placebo
Study: 27195774
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - IV and subcutaneous placebo
Study: 23077155
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid for 10 days (group I)
Study: 23077155
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone injection (ITDI) 4 times (group II)
Study: 23077155
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral steroid and ITDI (group III)
Study: 17994222
Drug: Routine prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine prescription of daily CXRs
Study: 17994222
Drug: Restrictive prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive prescription of clinically indicated CXRs
Study: 12802024
Drug: Increased-dose BEACOPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased-dose BEACOPP
Study: 9616817
Drug: Epinephrine nebulization
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine nebulization at 5 mg (A5)
Study: 9616817
Drug: Salbutamol nebulization
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol nebulization at 5 mg (S)
Study: 9616817
Drug: Epinephrine nebulization
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine nebulization at 2 mg (A2)
Study: 3935372
Drug: NORPLANT (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: NORPLANT (six capsules)
Study: 27123784
Drug: Atorvastatin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin plus Metformin (20 mg atorvastatin daily plus 500 mg metformin twice daily)
Study: 27123784
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 mg atorvastatin daily)
Study: 18725614
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of oral anticoagulant therapy after 6 months
Study: 18725614
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy (5-7 months after initiation)
Study: 15920039
Drug: Current therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current therapy (two or three shots per day using NPH insulin and rapid-acting analog)
Study: 12885745
Drug: Simvastatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (5 mg/d increased to 10 mg/d after 4 weeks)
Study: 10561302
Drug: Short interval
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short interval (SI) group: surgery within 2 weeks after completion of radiation therapy
Study: 10561302
Drug: Long interval
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long interval (LI) group: surgery 6 to 8 weeks after completion of radiation therapy
Study: 7995909
Drug: Gore-Tex sling
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gore-Tex sling treatment (alone or in combination with prolapsus cure)
Study: 7995909
Drug: Gore-Tex sling
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gore-Tex sling treatment
Study: 31090348
Drug: P-PRP (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-PRP (2.5 mL injected at the bone graft site)
Study: 31090348
Drug: L-PRP (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRP (2.5 mL injected at the bone graft site)
Study: 31090348
Drug: L-PRP
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRP
Study: 12535753
Drug: Fenofibrate intervention
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate intervention (not specified dosage or duration)
Study: 10433131
Drug: Combined psychoeducational
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined psychoeducational and cognitive treatment including key-person counselling
Study: 8688757
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg or 40 mg daily
Study: 1424414
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg per day)
Study: 2870547
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (100 mg per day in two doses)
Study: 30184181
Drug: TOL-463 vaginal
Normalized name: TOL-101
DrugBank: TOL-101 (DB16980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOL-463 vaginal gel
Study: 28183146
Drug: Prenatal ultrasound
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal ultrasound monitoring, interdisciplinary team approach, planned delivery through cesarean section, postnatal coverage of the intestine with a silastic bag, first intervention within the first 6 hours after birth, attempt of primary abdominal wall closure, perioperative antibiotic treatment.
Study: 28183146
Drug: Fetal therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fetal therapy, preterm delivery, lack of abdominal pressure monitoring.
Study: 27876742
Drug: Neuromidin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromidin therapy (1.5 month-long course) in addition to standard treatment
Study: 27876742
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without Neuromidin
Study: 12177686
Drug: Galantamine 24
Normalized name: galantamine 24 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 24 mg/day for 12 months
Study: 7059442
Drug: Lofexidine 0.1
Normalized name: lofexidine 0.18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofexidine 0.1 mg
Study: 7059442
Drug: Lofexidine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofexidine 0.3 mg
Study: 7059442
Drug: Lofexidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofexidine 0.6 mg
Study: 7059442
Drug: Lofexidine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofexidine (mean threshold dose)
Study: 28629250
Drug: Ginger (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (500 mg twice daily)
Study: 28629250
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 (40 mg twice daily)
Study: 2081722
Drug: Ciprofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (750 mg or 1000 mg bd)
Study: 2081722
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (rifampicin plus doxycycline)
Study: 370367
Drug: Sodium acetylo-salicylate
Normalized name: Sodium Salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium acetylo-salicylate (2 g per os) during heat exposure at 37 degrees C
Study: 370367
Drug: Sodium acetylo-salicylate
Normalized name: Sodium Salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium acetylo-salicylate (2 g per os) during exercise at 25 degrees C
Study: 23219660
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (Arm 1)
Study: 21965475
Drug: High-dose epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epirubicin plus cyclophosphamide (EC) - E 120 mg/m², C 600 mg/m² for four cycles every 21 days
Study: 21965475
Drug: Docetaxel (D)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (D) 100 mg/m² followed by four cycles of EC for four cycles every 21 days
Study: 11846927
Drug: Postoperative external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative external beam radiation therapy
Study: 9751087
Drug: cA2 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cA2 at 3 or 10 mg/kg with or without MTX
Study: 9751087
Drug: cA2 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cA2 at 1 mg/kg without MTX
Study: 9751087
Drug: cA2 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cA2 at 1 mg/kg with MTX
Study: 9751087
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus low-dose MTX
Study: 9751087
Drug: cA2 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cA2 at 10 mg/kg with MTX
Study: 9751087
Drug: cA2 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cA2 at 1 mg/kg alone
Study: 8176574
Drug: Clarithromycin suspension
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin suspension at 3.75, 7.5, and 15 mg/kg per dose every 12 hours
Study: 8176574
Drug: Clarithromycin suspension
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin suspension at 15 mg/kg per dose every 12 hours
Study: 8176574
Drug: Clarithromycin suspension
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin suspension
Study: 28843973
Drug: Carrot soup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrot soup with MSG (5 g, 1% w/w)
Study: 28843973
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein enriched carrot soup with MSG (5 g, 1% w/w)
Study: 17851077
Drug: Concomitant tumour
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant tumour bed boost (CB) with whole breast radiotherapy (RT) delivering 50Gy and an electron boost of 12.5Gy in 5 weekly fractions.
Study: 16375760
Drug: Walking Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking Program (WP) and Vitamin Supplements
Study: 16375760
Drug: Walking Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking Program (WP) and Placebo Supplements
Study: 16375760
Drug: Placebo Activity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Activity Program (PAP) and Vitamin Supplements
Study: 16375760
Drug: Placebo Activity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Activity Program (PAP) and Placebo Supplements
Study: 12452877
Drug: Oral antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antifungal agents
Study: 6114845
Drug: Dihydroergotamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine (2 mg)
Study: 6114845
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (2 mg dihydroergotamine and 20 mg etilefrine)
Study: 29358870
Drug: Study regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study regimen (oral sulfate solution 89 mL with diatrizoate solution: boost 1 = 60 mL, boost 2 = 30 mL)
Study: 29358870
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen (oral sulfate solution 89 mL)
Study: 25605861
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus trastuzumab (arms B and C)
Study: 17624483
Drug: Exercise programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise programme provided by public health nurses, comprising a weekly exercise class of 2 hours for 17 weeks, supplemented by daily home exercises
Study: 15112866
Drug: ReN1869 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReN1869 25 mg
Study: 15112866
Drug: ReN1869 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReN1869 50 mg
Study: 15112866
Drug: ReN1869 (subchronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReN1869 (subchronic mode, one week treatment)
Study: 2735337
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one tablet four times per day)
Study: 2735337
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg three times per day)
Study: 2735337
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g four times per day) plus Ranitidine (150 mg three times per day)
Study: 2735337
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Ranitidine (150 mg three times per day)
Study: 24715602
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (VP) 8% gel
Study: 15066608
Drug: High-fiber (13.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber (13.5 g/d) wheat bran fiber cereal supplement
Study: 15066608
Drug: Low-fiber (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fiber (2.0 g/d) wheat bran fiber cereal supplement
Study: 11495405
Drug: Buffered lidocaine
Normalized name: buffered lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered lidocaine with epinephrine solution
Study: 11495405
Drug: Combination buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination buffered lidocaine with epinephrine plus hyaluronidase solution
Study: 2648144
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid mouthwash (10 ml of a 4.8 percent aqueous solution)
Study: 31570881
Drug: Colorectal cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorectal cancer immunotherapy
Study: 21616946
Drug: Acamprosate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (2 g/day)
Study: 10792154
Drug: Controlled-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release oxybutynin tablets (10 mg once daily)
Study: 10792154
Drug: Conventional oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxybutynin tablets (5 mg twice daily)
Study: 9054629
Drug: 5 x
Normalized name: PAD,ABDOMINAL 5 X 9 STERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 x RDI VITE supplement (provided in cereal)
Study: 9054629
Drug: 30 x
Normalized name: Lead 30 X Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 x RDI VITE supplement (provided in capsules)
Study: 8311570
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 6 mg/kg dose of DEC
Study: 8311570
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 6 mg/kg dose of DEC preceded by 1 mg/kg DEC primer
Study: 8311570
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 220 micrograms/kg dose of ivermectin
Study: 8311570
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 200 micrograms/kg dose of ivermectin preceded by a 20 micrograms/kg ivermectin primer
Study: 8311570
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 400 micrograms/kg dose of ivermectin preceded by a 20 micrograms/kg ivermectin primer
Study: 3085896
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g elemental calcium plus 400 U Vitamin D
Study: 31999839
Drug: Dasatinib 100
Normalized name: dasatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 100 mg daily
Study: 26951136
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg bid per os for 3 days starting the day before biopsy
Study: 26951136
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g intravenously 1 hour prior to the procedure
Study: 24681657
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of ACEIs and ARBs on the day of surgery
Study: 24681657
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of ACEIs and ARBs
Study: 22691900
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OM) 20 mg (weeks 1-4), 40 mg (weeks 5-8)
Study: 22691900
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium (LOS) 50 mg (weeks 1-4), 100 mg (weeks 5-8)
Study: 15246631
Drug: HPV11 L1
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV11 L1 VLP vaccine (10 microg)
Study: 15246631
Drug: HPV11 L1
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV11 L1 VLP vaccine (20 microg)